Effects of minodronic acid and alendronate on bone remodeling, Microdamage accumulation, Degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys

Bone

Volumn 54, Issue 1, 2013, Pages 1-7

  Yamagami, Yoshiki ^a   Mashiba, Tasuku ^a   Iwata, Ken ^a   Tanaka, Makoto ^b   Nozaki, Kazutoshi ^c   Yamamoto, Tetsuji ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

^c ASTELLAS PHARMA INC   (Japan)

Author keywords

Alendronate; Bone microdamage; Mechanical property; Mineralization; Minodronic acid; Remodeling

Indexed keywords

ALENDRONIC ACID; MINODRONIC ACID;

ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BIOMECHANICS; BONE MASS; BONE MINERALIZATION; BONE REMODELING; BONE TURNOVER; CONTROLLED STUDY; CORTICAL BONE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FEMUR; HAPLORHINI; LOW DRUG DOSE; MORPHOMETRICS; NONHUMAN; OVARIECTOMY;

ALENDRONATE; ANIMALS; BIOMECHANICAL PHENOMENA; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CALCIFICATION, PHYSIOLOGIC; DIPHOSPHONATES; FEMALE; FEMUR; IMIDAZOLES; LUMBAR VERTEBRAE; MACACA FASCICULARIS; OVARIECTOMY;

EID: 84873505829     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.01.016     Document Type: Article

References (44)

1. Russell R.G., Rogers M.J. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999, 25:97-106.
2. Fleisch H. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991, 42:919-944.
3. Khan S.A., McCloskey E.V., Eyres K.S., Nakatsuka K., Sirtori P., Orgee J., et al. Comparison of three intravenous regimens of clodronate in Paget disease of bone. J Bone Miner Res 1996, 11:178-182.
4. Hosking D.J., Eusebio R.A., Chines A.A. Paget's disease of bone: reduction of disease activity with oral risedronate. Bone 1998, 22:51-55.
5. Fleisch H.A. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med 1997, 29:55-62.
6. Liberman U.A., Weiss S.R., Broll J., Minne H.W., Quan H., Bell N.H., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995, 333:1437-1443.
7. Black D.M., Cummings S.R., D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535-1541.
8. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077-2082.
9. Pols H.A., Felsenberg D., Hanley D.A., Stepan J., Munoz-Torres M., Wilkin T.J., et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999, 9:461-468.
10. Bauss F., Wagner M., Hothorn L.H. Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. J Rheumatol 2002, 29:990-998.
11. Matsumoto T., Hagino H., Shiraki M., Fukunaga M., Nakano T., Takaoka K., et al. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 2009, 20:1429-1437.
12. Tanaka M., Mori H., Kayasuga R., Ochi Y., Kawada N., Yamada H., et al. Long-term minodronic acid [ONO-5920/YM529] treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia. Bone 2008, 43:894-900.
13. Mori H., Tanaka M., Kayasuga R., Masuda T., Ochi Y., Yamada H., et al. Minodronic acid [ONO-5920/YM529] prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys. Bone 2008, 43:840-848.
14. Hagino H., Nishizawa Y., Sone T., Morii H., Taketani Y., Nakamura T., et al. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone 2009, 44:1078-1084.
15. Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int 2011, 22:2951-2961.
16. Allen M.R., Gineyts E., Leeming D.J., Burr D.B., Delmas P.D. Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int 2008, 19:329-337.
17. Allen M.R., Burr D.B. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 2007, 22:1759-1765.
18. Allen M.R., Iwata K., Phipps R., Burr D.B. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006, 39:872-879.
19. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000, 15:613-620.
20. Mashiba T., Turner C.H., Hirano T., Forwood M.R., Johnston C.C., Burr D.B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001, 28:524-531.
21. Goodman A.L., Descalzi C.D., Johnson D.K., Hodgen G.D. Composite pattern of circulating LH, FSH, estradiol, and progesterone during the menstrual cycle in cynomolgus monkeys. Proc Soc Exp Biol Med 1977, 155:479-481.
22. Jerome C.P., Carlson C.S., Register T.C., Bain F.T., Jayo M.J., Weaver D.S., et al. Bone functional changes in intact, ovariectomized, and ovariectomized, hormone-supplemented adult cynomolgus monkeys [Macaca fascicularis] evaluated by serum markers and dynamic histomorphometry. J Bone Miner Res 1994, 9:527-540.
23. Jerome C.P., Turner C.H., Lees C.J. Decreased bone mass and strength in ovariectomized cynomolgus monkeys [Macaca fascicularis]. Calcif Tissue Int 1997, 60:265-270.
24. Yoshida Y., Moriya A., Kitamura K., Inazu M., Okimoto N., Okazaki Y., et al. Responses of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized beagles with calcium restriction. J Bone Miner Res 1998, 13:1011-1022.
25. Balena R., Toolan B.C., Shea M., Markatos A., Myers E.R., Lee S.C., et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993, 92:2577-2586.
26. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2:595-610.
27. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000, 15:613-620.
28. Wenzel T.E., Schaffler M.B., Fyhrie D.P. In vivo trabecular microcracks in human vertebral bone. Bone 1996, 19:89-95.
29. Mori S., Harruff R., Ambrosius W., Burr D.B. Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures. Bone 1997, 21:521-526.
30. Komatsubara S., Mori S., Mashiba T., Ito M., Li J., Kaji Y., et al. Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 2003, 8:512-520.
31. Manabe T., Mori S., Mashiba T., Kaji Y., Iwata K., Komatsubara S., et al. Human parathyroid hormone [1-34] accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone 2007, 40:1475-1482.
32. Allen M.R., Burr D.B. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. Bone 2011, 49:56-65.
33. Saito M., Mori S., Mashiba T., Komatsubara S., Marumo K. Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporos Int 2008, 19:1343-1354.
34. Allen M.R., Reinwald S., Burr D.B. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3years of daily treatment. Calcif Tissue Int 2008, 82:354-360.
35. Ebetino F.H., Hogan A.L., Sun S., Tsoumpra M.K., Duan X., Triffitt J.T., et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone 2011, 49:20-33.
36. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 38:617-627.
37. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., Pak C.Y. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
38. Lenart B.A., Lorich D.G., Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008, 358:1304-1306.
39. Shane E., Burr D., Ebeling P.R., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267-2294.
40. Boivin G.Y., Chavassieux P.M., Santora A.C., Yates J., Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000, 27:687-694.
41. Roschger P., Rinnerthaler S., Yates J., Rodan G.A., Fratzl P., Klaushofer K. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 2001, 29:185-191.
42. Wasserman N., Yerramshetty J., Akkus O. Microcracks colocalize within highly mineralized regions of cortical bone tissue. Eur J Morphol 2005, 42:43-51.
43. Turner C.H. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 2002, 13:97-104.
44. Currey J.D. Physical characteristics affecting the tensile failure properties of compact bone. J Biomech 1990, 23:837-844.